Dabrafenib,Trametinib,Pembrolizumab
novartis,merck
['radio', 'melanoma']
excellent pathological response rates. as we have seen before, radiographic response doesn t correlate and is not a good predictor of path response. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4